GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (NAS:MOR) » Definitions » Notes Receivable

MorphoSys AG (MorphoSys AG) Notes Receivable : $0.0 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is MorphoSys AG Notes Receivable?

MorphoSys AG's Notes Receivable for the quarter that ended in Dec. 2023 was $0.0 Mil.


MorphoSys AG Notes Receivable Historical Data

The historical data trend for MorphoSys AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Notes Receivable Chart

MorphoSys AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

MorphoSys AG Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MorphoSys AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


MorphoSys AG Notes Receivable Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


MorphoSys AG (MorphoSys AG) Business Description

Address
Semmelweisstrasse 7, Planegg, BY, DEU, 82152
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.